The past, present and future of renin-angiotensin aldosterone system inhibition - Wikidata - awgldk - TriplyDB

The past, present and future of renin-angiotensin aldosterone system inhibition

The past, present and future of renin-angiotensin aldosterone system inhibition

http://www.wikidata.org/entity/Q34094354

about

Aerobic Exercise and Pharmacological Therapies for Skeletal Myopathy in Heart Failure: Similarities and Differences Stimulating endogenous cardiac repair The role of renin-angiotensin aldosterone system related micro-ribonucleic acids in hypertension Bedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients Who Do Not Meet Trial Enrollment Criteria Adrenal Diagnostics: An Endocrinologist's Perspective focused on Hyperaldosteronism Atrial Electrophysiological Remodeling and Fibrillation in Heart Failure A reappraisal of loop diuretic choice in heart failure patients Moderate inappropriately high aldosterone/NaCl constellation in mice: cardiovascular effects and the role of cardiovascular epidermal growth factor receptor.Endothelial Mineralocorticoid Receptors Differentially Contribute to Coronary and Mesenteric Vascular Function Without Modulating Blood Pressure.Impact of AT2-receptor stimulation on vascular biology, kidney function, and blood pressure.The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient.New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease.Role of MicroRNA in Endothelial Dysfunction and Hypertension.Effect of Angiotensin-converting Enzyme Inhibitor on Cardiac Fibrosis and Oxidative Stress Status in Lipopolysaccharide-induced Inflammation Model in Rats Evaluation of longitudinal left ventricular function in patients with coronary artery ectasia and vitamin D deficiency by 2D speckle tracking echocardiography.Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER).Gene-Gene Interactions Among PRKCA, NOS3 and BDKRB2 Polymorphisms Affect the Antihypertensive Effects of Enalapril.Within the Brain: The Renin Angiotensin System.Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.Inhibitory effect of D3 dopamine receptor on migration of vascular smooth muscle cells induced by synergistic effect of angiotensin II and aldosterone.

P2860

Q26767412-40978EAE-A416-401D-B219-D9A028FDD638 Q26781323-EECEA783-62AF-476C-8A11-C16DB0B360EA Q26786428-1AFD1FD2-EA8E-4DBA-B5BC-B14F5930EA53 Q26797153-C6931B9C-A310-4D9E-A06C-AD155BFABC73 Q27006954-7519D8FE-EB5A-4BC0-AA82-AFA464049652 Q28066307-07EB1EF4-1012-46B1-ABB8-7A02386E48EB Q28258044-F5D192E5-8D67-4501-AC32-F33879CCE97C Q34675520-802097B9-3272-4ADD-800F-DCFE0D0D6782 Q36143316-AD69DA0E-9C19-499D-AF61-9F51743DDF3F Q37416298-62836BEA-704D-4D10-A69A-B63FB2EDE5B1 Q38154260-0AA849FC-2756-470D-B4DA-AB52252B894B Q38845433-816B3DD3-0039-4CB3-ADB0-AD1BFBD06D0D Q39006068-302A053F-86B9-4B94-A313-5C8DD9CFF1D0 Q41665791-8078C33C-0D06-4AA9-A35B-9A9E788E5137 Q48285816-129A270B-3C2D-4325-9F57-F9AB576209AD Q51019622-0FCE1F9B-84FE-41C5-A501-5B501CDBB85B Q51437723-AC75C5CF-785E-433F-BD39-E4C4CDFA9EDF Q51762826-6F805070-8FC5-4807-A431-BFE16C5A881F Q53561964-D2248FE2-38B5-4AC0-9DBC-011205918514 Q53671992-572329E6-CF36-4C91-8D85-0AE6ED7029B0

P2860

The past, present and future of renin-angiotensin aldosterone system inhibition

http://www.wikidata.org/entity/Q34094354

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The past, present and future of renin-angiotensin aldosterone system inhibition

@ast

The past, present and future of renin-angiotensin aldosterone system inhibition

@en

The past, present and future of renin-angiotensin aldosterone system inhibition

@nl

type

label

The past, present and future of renin-angiotensin aldosterone system inhibition

@ast

The past, present and future of renin-angiotensin aldosterone system inhibition

@en

The past, present and future of renin-angiotensin aldosterone system inhibition

@nl

prefLabel

The past, present and future of renin-angiotensin aldosterone system inhibition

@ast

The past, present and future of renin-angiotensin aldosterone system inhibition

@en

The past, present and future of renin-angiotensin aldosterone system inhibition

@nl

P1433

Q34094354-387436A9-6F84-4424-A773-20E4131EE464

P1476

Q34094354-B9C1FD3F-5CEB-45DA-8939-B7760B0A18B0

P2093

Q34094354-01916F84-912C-418C-BC3D-632D4333DF42

Q34094354-504FF6F9-85AE-4878-BECD-2BE2792C36D1

Q34094354-828FCA01-7C82-4255-810C-ADC1E09F4A65

Q34094354-BF3A0E2C-136C-4BC7-BF8F-AE9FF9184445

Q34094354-D6C298CD-F0FB-46D7-B005-1E733A23286B

Q34094354-DA68CF13-3F5D-419B-99A4-741D87A31179

P2860

Q34094354-02A22D0A-3490-413E-ADE2-EEC01C7824B4

Q34094354-0483B724-50A5-4B31-80D4-B1DE608EBE59

Q34094354-0520B939-A310-4370-BC9E-2B512E080EA8

Q34094354-0690B2E5-D1F3-4DAA-820E-28879331DD89

Q34094354-06D26C3D-9242-42AA-A3CB-A2B4CAE9B727

Q34094354-07A4360C-0D06-464A-9B32-AC876EF738B7

Q34094354-07F93589-20F2-4789-8E6D-0DDE5CF98665

Q34094354-0B1F1C2F-99B2-4DE9-BA77-9CC49D631364

Q34094354-0BB2D1E1-9D61-45E8-A64B-D819DDF1F515

Q34094354-0C796BBA-670C-410F-8F3B-692A6A4AE68B

P304

Q34094354-725759EC-7256-42B7-BFD5-18ED40C7587E

P31

Q34094354-176EDD9B-26A5-444D-A8FD-20E874983188

P356

Q34094354-7FBEE1FD-8855-4E63-9EF8-4507E9A69EAE

P433

Q34094354-2609DBE4-DDB6-4750-9510-BCF8360A0BBA

P478

Q34094354-99838271-EC99-4D38-99B7-2775A9CD707D

P50

Q34094354-25B46792-2041-44FD-8D0C-3E6C406F70A2

Q34094354-2BBBDD80-53DD-45CB-B53D-5CCB3AB4A48D

Q34094354-5B4E1CB6-DE6E-48CE-903E-3F4DB5A87D58

Q34094354-9AD420D9-8663-43D2-BA04-F9EB56848A4E

Q34094354-AB3F199C-2BE4-4390-946F-01BB5883C46E

Q34094354-BCBE19B9-A054-484A-B987-8E19AE7EDAD0

Q34094354-DFB38982-37D2-4351-84CC-BB07A769CBAB

P577

Q34094354-E58B8544-D0F4-4030-B12D-ECB7CC46F59B

P698

Q34094354-B5E55FD2-4E70-467F-831E-C8AF5F30B313

P932

Q34094354-A4DA0DC4-0319-4540-B51A-CDBACB4D7FBA

P356

J.IJCARD.2012.10.007

P1433

International Journal of Cardiology

P1476

The past, present and future of renin-angiotensin aldosterone system inhibition

@en

P2093

Bernard Waeber

http://www.w3.org/2001/XMLSchema#string

George L Bakris

http://www.w3.org/2001/XMLSchema#string

Ileana L Piña

http://www.w3.org/2001/XMLSchema#string

John J V McMurray

http://www.w3.org/2001/XMLSchema#string

Mona Fiuzat

http://www.w3.org/2001/XMLSchema#string

Robert J Mentz

http://www.w3.org/2001/XMLSchema#string

P2860

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

Aldosterone antagonists for preventing the progression of chronic kidney disease

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

The underutilization of cardiac medications of proven benefit, 1990 to 2002

GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: de

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

P304

1677-1687

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJCARD.2012.10.007

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

167

http://www.w3.org/2001/XMLSchema#string

P50

Aldo P Maggioni

Luis Miguel Ruilope

Mihai Gheorghiade

Christopher M O'Connor

P577

2012-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23121914

http://www.w3.org/2001/XMLSchema#string

P932

4145865

http://www.w3.org/2001/XMLSchema#string